My impression is that much of this style of innovation is happening inside research institutes and then diffusing outward. There are plenty of people doing “boring” infrastructure work at the Sanger Institute, EMBL-EBI, etc. And you all get it for free! I can however see that on-demand services for biotech are a little different.
That’s very true, but I do think the translation to privatization can be useful! Helps push for better UI/UX, better support, and even better infra work. This isn’t true across the board, hard to imagine a company creating something like MMSeq, but I have to imagine its true in other areas
My impression is that’s a little simplistic, but I also don’t have the best knowledge of the market outside WGS/WES and related tools. That particular market is a bloodbath. Maybe there’s better scope in proteomics/metabolomics/stuff I know nothing about.
My impression is that much of this style of innovation is happening inside research institutes and then diffusing outward. There are plenty of people doing “boring” infrastructure work at the Sanger Institute, EMBL-EBI, etc. And you all get it for free! I can however see that on-demand services for biotech are a little different.
That’s very true, but I do think the translation to privatization can be useful! Helps push for better UI/UX, better support, and even better infra work. This isn’t true across the board, hard to imagine a company creating something like MMSeq, but I have to imagine its true in other areas
My impression is that’s a little simplistic, but I also don’t have the best knowledge of the market outside WGS/WES and related tools. That particular market is a bloodbath. Maybe there’s better scope in proteomics/metabolomics/stuff I know nothing about.